
IDEXX Q1 2021 Earnings Highlights (NASDAQ: IDXX)

Revenue		Opera Pro		Diluted Earnings Per Share					
\$778M		\$24	8M	\$2.3	\$2.35				
Reported growth:	+24%	31.8% of Revenue		Deported growth	+82%				
Organic growth:	+21% Yo	Y change in basis poin	its:	Reported growth:	10270				
CAG Diagnostics Recurrin	g Re	eported	+880 bps	Comparable growth:	+73%				
Organic Growth:	+23% Co	omparable	+830 bps	3					
😡 CAG		🚺 Wa	ter)				
Revenue \$	693M	Revenue	\$34M	Revenue	\$39M				
Reported growth:	+26%	Reported growth:	0%	Reported growth:	+15%				
Organic growth:	+22%	Organic growth:	-3%	Organic growth:	+9%				
Net CAG Revenue	Q1 Revenue	Reported Growth year over year y	Organic Growth rear over year	Q1 Premium Instrument Placements WW	North Intl America				
CAG Diagnostics Recurring	\$617M	+27%	+23%	Catalyst 1,73	31 665 1,066				
IDEXX VetLab [®] Consumables	\$246M	+30%	+26%	New and competitive 1,1	07 302 805				
Rapid Assay Products	\$70M	+21%	+20%	Premium Hematology 95	56 382 574				
Reference Laboratory Dx and Consulting Services	\$276M	+25%	+22%	SediVue® Dx 57	77 324 253				
CAG Diagnostics Services and Accessories	\$26M	+20%	+16%	TOTAL 3,26	64 1,371 1,893				
CAG Diagnostics Capital – Instrument	s \$31M	+31%	+27%						
Veterinary Software, Services and Diagnostic Imaging Systems	\$44M	+10%	+9%						

. . .

IDEXX

IDEXX Premium Instruments Installed Base



For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX's 2021 first quarter earnings release issued on May 4, 2021 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding.

2021 Growth and Financial Performance Outlook Commentary


- Increases outlook for 2021 revenue to \$3,105 million \$3,160 million, reflecting projected reported revenue growth of 14.5% 16.5% and organic revenue growth of 13% 15%, driven by 14.5% 16% CAG Diagnostics recurring revenue organic growth.
- Raises 2021 EPS estimate to \$7.88 \$8.18, reflecting a targeted operating margin improvement of 270
 320 basis points as reported and 150 200 basis points on a comparable basis. The updated EPS outlook reflects annual EPS growth of 17% 22% as reported and 21% 26% on a comparable basis.

wth and Financial Performance Outlook	2021		
Revenue	\$3,105	2	\$3,160
Reported growth	14.5%	-	17%
Organic growth	13%	-	15%
CAG Diagnostics Recurring Revenue Growth			
Reported growth	16%	-	17.5%
Organic growth	14.5%	-	16%
Operating Margin	28.3%	-	28.8%
Reported margin expansion	270 bps	-	320 bps
Comparable margin expansion	150 bps	-	200 bps
EPS	\$7.88	-	\$8.18
Reported growth	17%	-	22%
Comparable growth	21%	-	26%
Other Key Metrics			
Net interest expense	\$30	-	\$31
Share-based compensation tax benefit	~ \$16.5		
Effective tax rate	19%	-	20%
Reduction in average shares outstanding	0%	-	0.5%
Operating Cash Flow	100% - 110% of net income		
Free Cash Flow	80% - 90% of net income		
Capital Expenditures	\$120 - \$140		

Amounts in millions except per share data and percentages

For full financial data, non-GAAP reconciliations and cautionary language regarding forward-looking statements, please refer to IDEXX's 2021 first quarter earnings release issued on May 4, 2021 available at https://www.idexx.com/investors. Amounts presented may not recalculate due to rounding.





Total Practice Revenue and Visit Growth

Total visits include clinical and non-clinical visits. In 2020, there were an estimated 320 million U.S. total visits. Approximately 70% of estimated U.S. companion animal diagnostic market revenue is from non-wellness visits.

Clinical visits are those where the reason for visit involves an interaction between a clinician and a pet.


Non-wellness visits include those for which the reason for visit is sickness, procedure or monitoring.

Wellness visits include those visits for which the reason for visit is an annual exam, vaccination, or routine check-up.

Source: Based on analysis of IDEXX Practice Intelligence data (n = 7,915 practices). Growth rate estimate with margin of error of +/ - 0.4% at a 95% confidence level. * Note that we estimate net new practice formation adds ~1% of incremental market growth per year beyond *per practice* growth.

2020 Clinical Visits Including Bloodwork

'Bloodwork' represents chemistry and/ or hematology



Bloodwork utilization is defined as chemistry, hematology, or both run on one patient in a clinical visit.

The **percentage of clinical visits including bloodwork increased ~1% in 2020**, which is double the rate of annual increases seen in recent years, with year-over-year utilization increases across deciles as highlighted by the light blue pattern-filled areas in the bar chart.

Annual Trending of Clinical Visits Including Bloodwork 'Bloodwork' represents chemistry and/ or hematology % of U.S. Clinical Visits % of U.S. Wellness Clinical Visits % of U.S. Non-wellness Clinical Visits including Bloodwork including Bloodwork including Bloodwork 30% 30% 30% 23.4% 25% 25% 25% 22.2% 21.9% 20% 20% 17.8% 20% 16.9% 16.5% 15% 15% 15% 9.2% 8.7% 8.3% 10% 10% 10% 5% 5% 5% 0% 0% 0%

2019

2020

2018

2019

2020

Source: Based on analysis of IDEXX Practice Intelligence data (n = 7,804 practices). 'Clinical visits' are those where the reason for visit involves an interaction between a veterinary clinician and a pet, including wellness and non-wellness visit types. 'Bloodwork' represents chemistry and/ or hematology.

2018

2018

2019

2020